Right now, nonhuman primate models are only attainable following temporary changes, like adding the HBV entry receptor, a human protein called NTCP, to liver cells with the help of viral vectors.
It will also measure serum bile acid levels as a biomarker for the drug's engagement with the sodium taurocholate cotransporting polypeptide (NTCP), which HDV uses to infect liver cells.